Introduction
============

*Blastocystis* spp. (referred to as *Blastocystis* in the manuscript) is a unicellular eukaryotic microorganism that belongs to the Stramenopile phylum. This phylum encompasses an extremely large diversity of organisms including free-living flagellates, parasites of plants (for example, *Peronospora*) and animals (for example, *Phytium insidiosum*), organisms resembling fungi in terms of cytology and ecology, and a myriad of photosynthetic lineages that range from single-cell diatoms to giant multicellular brown algae ([@bib18]). *Blastocystis* is a common inhabitant of the gut of humans and other animals ([@bib16]). Its prevalence in humans varies within and between populations, but it is higher in underdeveloped countries, where it can reach 100% ([@bib20]). This is likely the result of poor hygiene conditions, contact with animal reservoirs, and consumption of contaminated water or food ([@bib70]). Isolates of *Blastocystis* from different hosts are morphologically very similar, yet display substantial genetic variability: based on nucleotide differences in the small subunit ribosomal DNA gene, 17 different subtypes (STs) are recognized, nine of which (ST1 to ST9) are associated with human colonization ([@bib70]; [@bib2]). Previous studies reported the presence of *Blastocystis* in all continents ([@bib1]), attesting its ubiquitous distribution, but the overall epidemiological picture is still incomplete.

Whether *Blastocystis* is to be considered a pathogen, a commensal or even a beneficial member of the human gut microbiome is still unclear ([@bib39]). Indeed, some studies have implicated it in intestinal diseases, including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), thus supporting a pathogenic potential ([@bib69]). Further, genome analysis of an ST7 isolate revealed the presence of genes encoding potential virulence factors, notably hydrolases and serine and cysteine proteases ([@bib17]). On the other hand, studies of healthy, randomly sampled individuals have shown a high carriage of *Blastocystis* and a prolonged colonization of the gut ([@bib59]; [@bib60]). Therefore, unbiased large-scale investigations are needed to clarify its role as an etiological agent of disease, but targeted epidemiological investigations of *Blastocystis* at a global scale are impractical.

Cultivation-free, sequencing-based metagenomic technologies ([@bib74]; [@bib75]; [@bib42]; [@bib63]) can potentially overcome some of these issues. Many large-scale metagenomic studies have been performed to characterize the complex consortium of organisms constituting the human gut microbiome, and recent strain-level analyses started to unravel the population structure of bacterial species ([@bib61]; [@bib72]) but little attention has been devoted to intestinal parasites ([@bib5]). Indeed, until now, only one investigation ([@bib4]) used a metagenomic approach to study *Blastocystis* within 316 samples of the MetaHIT data set ([@bib51]) and there is thus the unmet opportunity to exploit larger sets of metagenomes for parasite profiling and epidemiology.

In order to expand the size, genetic depth, and host population diversity of epidemiologic investigation, we developed a bioinformatic pipeline to detect the presence of *Blastocystis* from metagenomes, and applied it on 12 published large metagenomic data sets of the human gut microbiome. Overall, 1689 subjects from 18 different countries and 4 continents (Europe, Africa, Asia and North/South America) were studied, allowing us to survey the prevalence, ST distribution, and genome characteristics of the microorganism, and to investigate its association with disease conditions and the structure of the resident gut bacterial population.

Materials and methods
=====================

Metagenomic data sets and data pre-processing
---------------------------------------------

We analyzed 2154 publicly available gut metagenomic samples from twelve studies. We considered the nine largest metagenomics studies we were aware of and were available as of July 2015 to which we added three additional studies to expand the geographical span of our analysis ([Table 1](#tbl1){ref-type="table"}). The selected raw metagenomes were processed with FastqMcf ([@bib7]) by trimming positions with quality \<15, removing low-quality reads (mean quality \<25), and discarding reads shorter than 90 nt. Human DNA and Illumina spike-in DNA (Bacteriophage phiX174) were then removed by using BowTie2 ([@bib33]) to map the reads against the reference genomes.

Eight of the considered studies aimed at characterizing the human gut in different health conditions whereas four considered subjects not affected by documented medical conditions ([Table 1](#tbl1){ref-type="table"}). We collected and manually curated the main available metadata associated with the samples ([@bib49]). The metadata fields considered here are body mass index (BMI), age, gender and disease status. We made the complete metadata table associated with the samples publicly available at <https://bitbucket.org/CibioCM/metaml/src> and inside the curatedMetagenomicData package ([@bib48]).

We performed the analysis using the 9 available genomes of *Blastocystis* subtypes as reference. These include the complete genome sequence of one isolate from ST7 ([@bib17]) and one from ST4 (accession codes CABX01000000 and JPUL02000000, respectively). Additionally, we used the draft genomes of other STs (ST1, ST2, ST3, ST4, ST6, ST8 and ST9) isolated from humans that have been recently deposited in public databases (accession codes LXWW00000000, JZRJ00000000, JZRK00000000, JZRL00000000, JZRM00000000, JZRN00000000, JZRO00000000). Before using these genomes in our analysis, and because *Blastocystis* sequencing projects are likely to contain DNA from other organisms, we screened all contigs of all assemblies for potential bacterial and archaeal contamination. We did this by mapping with BLASTN the *Blastocystis* assemblies against the set of \~55 000 publicly available archaeal and bacterial genomes. By considering matches over at least 500 nucleotides and a nucleotide identity of at least 90%, we removed all contigs with bacterial or archaeal matches over more than 3% of the length of the contig. Overall, we removed 613 contigs after screening out a minimum of 246 384 nucleotides for ST4 and a maximum of over 4.5 M nucleotides for ST6 ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). We notice that our procedure was set to be quite aggressive in avoiding potential contamination, but this is a safe strategy for our investigation as more than 10 M nucleotides remained available for all ST and these are largely sufficient to assess the presence of *Blastocystis* in metagenomes as reported below.

Detection of *Blastocystis* STs from metagenomes
------------------------------------------------

Metagenomic reads were mapped to reference genomes using the Bowtie2 aligner ([@bib33]) and an end-to-end alignment for paired ends reads. The Bowtie2 output was processed by Samtools ([@bib36]) and the sorted and indexed BAM file was processed with BEDtools ([@bib54]) to compute the breadth of coverage for each subtype ('genomecov --bg' parameter), which represents the fraction of the target genome covered by at least one metagenomic read ([@bib41]). The relative abundance in subjects colonized over two timepoints was estimated by counting the number of reads mapped to the *Blastocystis* reference genome normalized by the total number of reads in the sample.

In this work, we define a sample as positive for a *Blastocystis* ST if its genome has a breadth of coverage of at least 10%. This value was chosen based both on (i) the similarity between the genomes of different *Blastocystis* STs and (ii) on the false positive detection rate for the presence of a second *Blastocystis* ST when another one is present. For the first criteria, we quantified the average fraction of the genome of a *Blastocystis* ST shared at a sequence similarity higher than 80% with a distinct *Blastocystis* ST genome using LAST ([@bib28]) ('-l 100 -f BlastTab' parameters). The maximum fraction of matching genome was 3%, with the only exceptions of ST4--ST8 and ST6--ST9 which share more than 15% of the genome. However, this value substantially decreases at percentage identity thresholds \>80% which is a very conservative threshold considering that the maximum identity at which a read of 100 nt can be mapped against a reference genome is 95%. Additionally, at the 10% breadth of coverage threshold, we did not find any co-occurrence of ST4 and ST8 in the samples, and for the cases in which ST6 and ST9 co-occurred we manually confirmed that most of the reads outside the shared genomic regions mapped only against the ST with the highest breadth of coverage. For the second criteria, we looked at the distribution of the number of additional STs in addition to the one with the largest breadth of coverage detected when varying the threshold ([Supplementary Figure 9](#sup1){ref-type="supplementary-material"}). This distribution goes from seven (all the STs in addition to the dominant one) to one (only the dominant ST detected), but it is already plateauing at 10% breadth of coverage confirming that such value does not produce false positives. Multiple lines of evidence thus support the 10% breadth of coverage value to be safe in avoiding false positives. False negatives would be minimized at lower threshold value, but false negatives are arguably less problematic than false positives, and false negatives are an intrinsic and unavoidable problem in metagenomics.

Assessing the limit of detection for *Blastocystis* in metagenomes
------------------------------------------------------------------

To assess the sensitivity of our procedure in detecting *Blastocystis*, we performed semi-synthetic experiments by spiking-in known amounts of synthetic reads from known *Blastocystis* genomes into real *Blastocystis*-negative gut metagenomes. For each ST, the synthetic reads were obtained with an Illumina-based sequencing simulator with typical sequencing error rates and noise ([@bib40]). As real *Blastocystis*-negative gut metagenomes we considered metagenomes from the HMP, Karlsson, LeChatelier, and Obregon-Tito data sets subsampled after QC to the typical metagenome size of 50M reads. The procedure was repeated at multiple fractions of *Blastocystis* relative abundance from 0.001 to 1% (for a total of 30 abundance values) and considering seven distinct real gut microbiomes for each simulation and ST. With this analysis ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), we empirically found that the chosen detection threshold (10% breadth of coverage) corresponds to a limit of detection slightly below 0.03% abundance. ST7 has an even lower limit of detection which is due to the length of its genome (about 50% larger than the other STs). As mentioned above, our *Blastocystis* detection pipeline aims at minimizing the false positive rate, so even though thresholds lower than 10% breadth of coverage would positively impact the limit of detection, we again preferred to avoid calling the presence of *Blastocystis* without strong quantitative evidence. The limit of the detection of our procedure is higher than what can be achieved with PCR-based approaches, that are however limited in the amount of genomic information that they can provide.

Metagenomic assembly and *Blastocystis* contig binning
------------------------------------------------------

The 43 metagenomic samples in which we detected a breadth of coverage higher than 66.6% for at least one *Blastocystis* genome, were selected for *de novo* metagenomic assembly. This was performed using SPAdes version 3.9.0 ([@bib9]). Contigs shorter than 1000 nt were discarded, and contigs from *Blastocystis* identified by mapping with BLASTN the screened contigs against the *Blastocystis* reference genomes. Specifically, we assigned a contig to a *Blastocystis* subtype if it had at least 90% identity over at least half of its length against the available reference genome.

Whole-genome phylogenetic analysis
----------------------------------

To infer the phylogeny of the newly assembled genomes we adopted a core gene based strategy ([@bib64]; [@bib46]). The core gene set was generated by aligning all the annotated genes of the *Blastocystis* ST4 WR1 genome against all 8 available reference genomes and the 43 genomes we newly assembled using BLASTN (Evalue: 1e-50, word size:9). To be included in the core gene set, a gene was required to be present in at least 75% of the analyzed genomes with an identity higher than 65% over at least 600 bp. The identified core gene sequences were then aligned using MUSCLE ([@bib19]), concatenated in a single alignment, and processed with trimAL ('-gappyout' parameter) ([@bib14]) to remove excessively gapped sub alignments and poorly aligned regions. The phylogeny was then built using RAxML version 8.1.15 ([@bib67]) with the GTRGAMMA model and 100 bootstrap steps.

Using this approach, we identified a core gene set of 9 genes (average alignment length of each gene of 2443 bp and standard deviation of 1374 bp) for a total concatenated alignment length of 21 984 bp. To improve the resolution at a lower phylogenetic level, we repeated the process within the genomes of ST1, ST2, ST3 and ST4 separately and reconstructed their intra subtype phylogeny on which a larger shared core genome can be identified. Subtype-specific trees were generated by fragmenting each genome in portions of 2000 bp and treating them as genes because no genome annotation was available and *de novo* annotation would have introduced biases. Criteria for the inclusion in the core gene adapted to the intra-ST case included the requirement that a sequence was present in all the genomes with an identity higher than 95%. Single-nucleotide variant distribution within every subtype was calculated using nucmer ([@bib32]) pipeline for computing pairwise alignment and SNV reporting. For ST1 the average pairwise alignment was 3 431 933 bp (s.d. 2 323 310 bp), for ST2 3 876 563 bp (s.d. 1 985 719 bp), for ST3 2 318 013 bp (s.d. 2 917 467 bp) and for ST4 3 432 010 bp (s.d. 3 131 603 bp).

Functional prediction and annotation
------------------------------------

We considered the 19 reconstructed genomes accounting \>5 Mbp for gene prediction and annotation. *Ad initio* gene prediction was performed using SNAP ([@bib30]) to generate HMM models for all the STs using the available annotations to build the HMM reference profile. Genome annotation was performed using MAKER ([@bib13]) with default parameters using the HMM models previously generated. Newly predicted proteins were then functionally annotated with eggnog-mapper ([@bib24]) using the eggNOG ([@bib25]) Eukaryotic data set. ST-specific KOG functions were determined by performing a Fisher\'s exact test between the genomes of a particular ST and the other ones. Adjusted *P*-values were computed through the false-discovery rate correction.

Microbiome profiling and co-occurrence analysis
-----------------------------------------------

All samples were processed with MetaPhlAn2 ([@bib66]; [@bib71]) to quantitatively profile the whole microbial population exploiting the properties of species-specific markers ([@bib23]). We used the obtained abundance profiles to investigate the co-occurrence or co-exclusion ([@bib21]) of *Blastocystis* with other members of the microbiome. In particular, the Wilcoxon rank-sum test was used to identify the microbial features that were associated with the presence or absence of *Blastocystis*. In computing this test, duplicates from the same subject were discarded and a threshold of 0.05 was considered as significance level. Additional analysis for finding bacterial clades associated with *Blastocystis* presence was performed using the LEfSe (LDA effect size) tool ([@bib65]). Finally, a machine learning-based approach was applied to further investigate if the microbiome signature is predictive for the presence of *Blastocystis*. The species abundances generated by MetaPhlAn2 were used to discriminate between *Blastocystis*-positive and negative samples. For this purpose we considered a random forest (RF) classifier ([@bib11]) implemented in the MetAML tool ([@bib49]). First, prediction accuracies were assessed by an unbiased 10-fold cross-validation procedure, repeated and averaged over 20 independent runs. Then, we applied a leave-one-data set-out approach, in which the presence of *Blastocystis* in a given data set is predicted by training the model on the samples from the other independent studies. Prediction accuracies were evaluated in terms of area under the ROC curve (AUC) statistics, which can be interpreted as the probability that the classifier ranks a randomly chosen positive sample higher than a randomly chosen negative one, assuming that the positive sample ranks higher than the negative one. The free parameters of the classifiers were set as follows: (i) the number of decision trees was equal to 500; (ii) the number of features to consider when looking for the best split was equal to the root of the number of original features; (iii) the quality of a decision tree split was measured using the Gini impurity criterion. The software framework used for this experiment is open-source and available online at <http://segatalab.cibio.unitn.it/tools/metaml>. Alpha diversity was computed for each data set by considering Gini-Simpson and Shannon indexes under the condition of presence or absence of *Blastocystis* and the Student's t-test (significance level set to 0.05) was used to test significance between the two conditions.

Results
=======

Meta-analysis for *Blastocystis* in large metagenomic data sets
---------------------------------------------------------------

We screened large-scale intestinal metagenomic data sets to assess the prevalence of *Blastocystis* and its STs, infer epidemiologic characteristics, and examine the characteristics of their genomes. Overall, we processed 2154 fecal microbiome samples from 1,689 subjects from 12 data sets ([Table 1](#tbl1){ref-type="table"}). These data sets span diverse disease conditions including colorectal cancer ([@bib81]), type 2 diabetes ([@bib52]; [@bib27]), liver cirrhosis ([@bib51]), obesity ([@bib34]) and IBD ([@bib51]; [@bib43]). All these studies almost exclusively focused on the bacterial components of the microbiome and did not report the presence of microbial Eukaryotes, with the above mentioned exception that focused on a single metagenomic data set ([@bib4]). The wide range of distinct health conditions and geographic origins of the hosts we considered here are thus a key factor in this study.

To assess the presence of *Blastocystis,* we used a sequence mapping based approach aided by the availability of draft genome sequences from eight subtypes (ST1, ST2, ST3, ST4, ST6, ST7, ST8 and ST9), all known to be associated with human colonization. After removing potential bacterial sequences contaminating these genomes (see Materials and methods and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}), we estimated the fraction of each target genome covered by metagenomic reads (that is, the breadth of coverage) and we considered samples positive for *Blastocystis* when the breadth of coverage was higher than 10% (see Materials and methods). Using this approach, *Blastocystis* is detected when present at a concentration as low as 0.03% in typical metagenomic samples of 50M reads ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Downstream analyses detailed in the rest of the work are based on this detection threshold.

Blastocystis prevalence and subtype dominance is biogeographically variable
---------------------------------------------------------------------------

We first determined the prevalence of *Blastocystis* in the overall data set, which included 2154 fecal samples from 1689 subjects. The microorganism was detected in 321 samples, originating from subjects in ten countries (China, Denmark, France, Mongolia, Norway, Peru, Spain, Sweden, Tanzania and USA) from four continents, with an overall prevalence of 14.9%. The prevalence was higher in European subjects (243 of 1084 samples, 22.4%) and lower in Chinese ones (24 of 600, 4.0%). Despite the relatively small size of the data set, 15 (55.6%) of the 27 Tanzanian subjects ([@bib56]) were positive for *Blastocystis*, whereas all the Italian subjects (*n*=11) from the same study were negative. *Blastocystis* was not detected in the Shiga toxin-producing *Escherichia coli* (STEC)-infection data set ([@bib38]).

The prevalence of *Blastocystis* appears to be influenced by the DNA extraction procedure used in the different studies, being higher when methods combining mechanical and chemical lysis steps are used ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). This suggests that efficient DNA extraction from lysis-resistant microorganism cysts requires appropriate procedures, and that comparison across studies should consider this factor ([@bib79]). On the other hand, cohort differences may have a larger impact on prevalence than methodological aspects, as exemplified by large differences in prevalence between three European data sets (LeChatelier, MetaHIT and Nielsen) and the Chinese T2D data set, despite the use of the same DNA extraction procedure.

We then examined the prevalence of the different *Blastocystis* STs among individuals colonized with single STs ([Figure 1](#fig1){ref-type="fig"}; [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). While some aspects such as the wide geographic distribution of ST3 (detected in 10 of 12 data sets), and the overall low prevalence of ST6, ST7 and ST9, are in agreement with the current global epidemiologic information ([@bib16]), two new points of particular relevance emerged. First, ST2 appears to predominate in the non-industrialized cohorts analyzed, which are hunter-gatherer populations from Tanzania ([@bib56]) and Peru ([@bib45]; [Figure 1](#fig1){ref-type="fig"}). The difference in ST2 prevalence between non-westernized (including data from ([@bib37])) and westernized individuals is highly statistically significant (*P*=6E−10). This raises the hypothesis that ST2 is one of the members of the gut microbiome that have been affected by westernization processes ([@bib62]). Second, the prevalence of ST4 is very high among European subjects ([Figure 1](#fig1){ref-type="fig"}), which is in sharp contrast with the absence, or extreme rarity, of this ST in other regions of the world (for example, *P*=7E−16 for the difference in prevalence between Europe and Asia, [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}), except the US. The difference in ST4 prevalence between westernized and non-westernized individuals is also statistically significant (*P*=0.046). These data confirm and extend previous observations on the peculiar geographical distribution of ST4 ([@bib22]). Overall, ST2 and ST4 thus appear to be the *Blastocystis* subtypes most influenced by geography and lifestyles.

Blastocystis prevalence is higher in subjects with low BMI and in healthy controls for Crohn's disease and colorectal cancer
----------------------------------------------------------------------------------------------------------------------------

We tested the association between the presence of *Blastocystis* and available parameters of interest (see Materials and methods), and found that BMI is strongly negatively correlated with *Blastocystis* prevalence. In the metagenomic study that specifically targeted the obesity phenotype ([@bib34]), we detected *Blastocystis* in 39.4% normal weight individuals, compared with 15.4% obese subjects (*P*=2E−05, [Figure 2a](#fig2){ref-type="fig"}). This is consistent with findings from a study of Danish subjects ([@bib4]). The other data sets include a smaller number of obese subjects, thus providing less statistical power to test the association. Nonetheless, a higher *Blastocystis* prevalence in normal weight individuals compared with overweight and obese ones was evident in six of the eight data sets, two of which supported by statistical significance ([Figure 2a](#fig2){ref-type="fig"}).

Interestingly, when considering all the European data sets that used the same collection and processing protocols (*n*=715, 126% more samples than ([@bib4])), the difference in *Blastocystis* prevalence between normal weight and obese subjects was again strongly significant (*P=*5E−03), as it was between normal weight and overweight (*P*=0.01), and between non-overweight and overweight (*P*=0.02). At the level of specific subtypes, only ST4 reached statistical significance (*P*=0.03 between normal weight and obese), suggesting that association between *Blastocystis* and BMI is probably not subtype-specific.

We did not find an increased prevalence of *Blastocystis* in subjects affected by any of the considered diseases (lowest one-side *P*=0.4 for T2D in the Karlsson data set). Conversely, *Blastocystis* was positively associated (*P*=0.008) with the control group in the colorectal cancer data set ([@bib81]), with only 3 of the 53 (5.7%) patients positive for the microorganism compared with 15 of the 61 (24.6%) healthy controls ([Figure 2b](#fig2){ref-type="fig"}). This trend was also confirmed in the same data set when considering patients with large adenomas (*n*=14), as only one was positive for *Blastocystis*. Crohn's disease, but not ulcerative colitis, was also negatively associated with the presence of *Blastocystis* (*P*=0.04). Our findings seem to contrast other reports especially for colorectal cancer ([@bib31]), whereas for IBD existing data already associated ulcerative colitis rather than Crohn's disease with decreased *Blastocystis* prevalence ([@bib50]) although different conclusions were reached in other reports ([@bib15]). Previous data on this association are however sparse, debated in clinical settings, and potentially affected by publication bias. More independent investigations are needed to elucidate these relations, but our results suggest that the ecological niche of *Blastocystis* is independent from disease-associated microbiome dysbiosis features. A further hypothesis supported by the above associations and the absence of *Blastocystis* in STEC-positive subjects, is that *Blastocystis* is actually less common in individuals with gastro-intestinal symptoms and other microbiome-associated disease conditions ([@bib60]).

Stable *Blastocystis* colonization is subtype-independent
---------------------------------------------------------

To study the persistence of *Blastocystis* colonization and determine the subtypes involved in chronic colonization, we analyzed the metagenomic data set of subjects who provided stool samples at multiple timepoints. A total of 121 subjects, 43 from the HMP data set ([@bib26]) and 78 from the Nielsen data set ([@bib43]), were sampled at two timepoints (mean 219 and 163 days after first sampling, respectively). *Blastocystis* was identified above the detection threshold in 22 subjects (7 from HMP and 15 from Nielsen) in at least one of the timepoints considered ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Of the 22 positive subjects, 14 (64%) maintained the colonization over the two timepoints, whereas five subjects acquired and three subjects lost the colonization between the two timepoints ([Figure 3a](#fig3){ref-type="fig"}; [Supplementary Table 3](#sup1){ref-type="supplementary-material"}). For the cases of colonization acquisition/loss and accordingly with our detection limit of 0.03% relative abundance, *Blastocystis* is indeed absent in the subject or may be present at very low abundance which is still indicative of variations in the ecological relation of *Blastocystis* with the resident microbiome. In subjects with stable colonization, the relative abundance of *Blastocystis* changed only slightly in the majority of the cases ([Figure 3b](#fig3){ref-type="fig"}) and we did not observe variations higher than three folds.

In the 14 subjects with stable colonization, we always found the same ST at the two timepoints, suggesting that ST replacement is not a frequent event in the healthy human gut, at least over the relatively short timeframes considered in the data sets ([Figure 3](#fig3){ref-type="fig"}). The subtypes commonly found in humans (ST1--ST4) all appeared as stable colonizers, suggesting that this phenomenon is not subtype dependent.

Whole-genome genetic analysis of *Blastocystis* subtypes
--------------------------------------------------------

Isolates belonging to the same *Blastocystis* subtype display some genetic variability, as highlighted by studies of ribosomal markers ([@bib80]) and a few housekeeping genes ([@bib68]; [@bib80]). However, the extent of polymorphism at the genome level and variability in gene content within different STs is unknown. To this end, we reconstructed draft *Blastocystis* genomes from the metagenomes and performed comparative genomic analysis. In total, 43 assemblies were obtained using metagenomic assembly with SPAdes ([@bib9]) followed by binning and taxonomic assignment (see Materials and methods, [Supplementary Table 4](#sup1){ref-type="supplementary-material"}) from the samples with very high *Blastocystis* abundance. Specifically, 16 new genomes were very closely related to the available genome of ST4, 7 to ST2 and ST1, 9 to ST3, whereas only 4 genomes were assembled from the phylogenetically related ST6, ST8 and ST9. A simple genetic feature such as the average GC content ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}) was already distinctive across STs, in that ST1, ST2 and ST3 that have a genome much richer in GC (average 52.6%, 52.0%, 51.5% respectively) than ST4, ST8 and ST9 (average 40.0%, 42.3% and 41.5% respectively), whereas ST6 is in between these two groups (average 44.9%).

We then integrated the nine available genomes with the 43 new assemblies to reconstruct the genome-scale phylogeny of the *Blastocystis* genus using the concatenation of aligned core genomic fragments. This reconstruction relies upon the substantial fraction of the genome that is conserved across strains and have been performed for assemblies with an average of 4.4 Mb of reconstructed genome ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). While the overall structure of the tree ([Figure 4a](#fig4){ref-type="fig"}) confirms previous phylogenetic analyses based on single marker genes ([@bib80]) and ST-specific phylogenies consistently place the reconstructed genomes from multiple sample of the same patient ([Figure 4d](#fig4){ref-type="fig"}), substantial genetic diversity is detected within each ST ([Figures 4b and e](#fig4){ref-type="fig"}). Strains belonging to ST1 show the highest genetic diversity with, on average, 1.5% (s.d. 0.10%) single-nucleotide substitutions in the genomic regions conserved between pairs of strains ([Figure 4f](#fig4){ref-type="fig"}). ST4 shows instead an overall much higher sequence conservation (average 0.27% s.d. 0.14% divergence), in agreement with findings from single marker genes ([@bib68]). ST2 and ST3 display intermediate genetic diversity compared with ST1 and ST4.

We then restricted the genomic analysis to the 19 genomes for which at least 5 Mb have been reconstructed and performed a functional annotation and characterization of these high-quality assemblies (4 for ST1, 4 for ST2, 4 for ST3, and 7 for ST4, see [Supplementary Table 4](#sup1){ref-type="supplementary-material"}) by using the eggNOG ([@bib25]) database (see Materials and methods). Unsurprisingly, less than half of the genes identified were assigned to known COG functional categories (from 42.7% of ST4 to 46.7% of ST3, [Figure 5a](#fig5){ref-type="fig"}). Only few categories were not represented in *Blastocystis* (for example, as expected, the cellular machinery for cell motility) and the four STs generally contained a very similar number of proteins in these broad categories ([Figure 5b](#fig5){ref-type="fig"}). The only exceptions are category J (Translation, ribosomal structure and biogenesis) and category A (RNA processing and modification) that are overrepresented in the genomes of ST3 and underrepresented in those of ST2 (*P*\<1E−04), as well as categories D (Cell cycle control and mitosis) and T (Signal Transduction, all *P*\<1E−04). More specific functional assignments based on the manually curated Clusters of Orthologous Groups for Eukaryotes (KOG, see [Supplementary Table 5](#sup1){ref-type="supplementary-material"}; [@bib25]) further highlighted the differences in functional potential between STs and the substantial intra-ST functional consistency. This is clear from the hierarchical clustering analysis of the KOG profiles in each reconstructed genome ([Figure 5c](#fig5){ref-type="fig"}), in which the close phylogenetic relationship between strains in the same ST is recapitulated at the level of their functional potential. A total of 795 KOGs were found to be ST-specific ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}; [Supplementary Figure 5](#sup1){ref-type="supplementary-material"}) after statistical significance testing with false-discovery rate correction (see Materials and methods). For example, a cystatin (0IZK7 Cystatin B), that in ST7 has a potential role in parasitic cysteine protease and inhibition of host proteases ([@bib17]; [@bib77]), is present in ST2 but not in ST1, ST3, and ST4. Likewise, we found a glycoside hydrolase (hydrolase family 47) only in ST3, and this may be involved in the attack of the host intestinal epithelial cells ([@bib17]). Finally, in ST4 genomes we found heat shock proteins (like 0PHA3 and KOG3047---ubiquitously-expressed, prefoldin-like chaperone) and cytosolic Ca2+-dependent cysteine proteases (like KOG0045---Calpain-like cysteine peptidase) that were not present in other ST genomes, and these may represent virulence factors unique to this ST. Altogether these data indicate that different *Blastocystis* STs have distinct functional potential niches that are currently only partially characterized. Further, we show for the first time that it is possible to characterize ST-specific functional repertoires that are conserved among strains of the same ST.

The presence of *Blastocystis* is highly correlated with gut microbiome composition
-----------------------------------------------------------------------------------

We found a very strong association between the presence of *Blastocystis* and the abundance of archaeal organisms (*P*\<7E−37). On the overall data set, this association may be inflated because some DNA extraction procedures may favor non-bacterial organisms ([@bib78]), but we observed strong statistical significance in all but two single data sets ([Figure 6](#fig6){ref-type="fig"} and [Supplementary Table 6](#sup1){ref-type="supplementary-material"}). Archaea in the human gut are represented primarily by *Methanobrevibacter smithii* ([Figure 6a](#fig6){ref-type="fig"}) which is in fact strongly associated with the presence of *Blastocystis*. Interestingly, several archaeal genes, likely acquired horizontally, are present in the *Blastocystis* genome ([@bib17]), suggesting that the common ecological niche favors the interaction and the exchange of genetic material between the microorganism and the Archaea.

Several bacterial clades were also found to be strongly associated with *Blastocystis* presence, with a total of 68 significant associations with effect size larger than 3.3 as found by LEfSe analysis ([@bib65]) ([Figure 6e](#fig6){ref-type="fig"}; [Supplementary Figure 6](#sup1){ref-type="supplementary-material"}). Bacteria in the *Firmicutes* phylum and in the *Clostridiales* order also appeared strongly enriched in samples positive for *Blastocystis* ([Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). Species in this order included *Butyrivibrio crossotus* (significant in 7 data sets, [Figure 6b](#fig6){ref-type="fig"}), *Eubacterium siraeum* (significant in 6 data sets, [Figure 6c](#fig6){ref-type="fig"}), and *Coprococcus catus* (significant in 6 data sets, [Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). In addition, the overall Clostridiales order is associated with the presence of *Blastocystis* ([Supplementary Table 6](#sup1){ref-type="supplementary-material"}). However, some clostridia tend to co-exclude with *Blastocystis*, such as *Ruminococcus gnavus* (significant in 6 data sets, [Figure 6d](#fig6){ref-type="fig"}) and *Clostridium bolteae* (significant in 5 data sets, [Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). Therefore, while there is a general positive association between *Firmicutes*/*Clostridia* and *Blastocystis*, there are negative associations at the species-level, possibly due to competition for resources or different ecological niches.

In contrast, the most abundant intestinal bacterial genus, *Bacteroides*, is generally more abundant in *Blastocystis*-negative samples ([Supplementary Figure 7](#sup1){ref-type="supplementary-material"}), with five data sets in which this trend is significant. This association is also driving the general higher abundance of the Bacteroidetes phylum in *Blastocystis*-negative samples and possibly contrasting the opposite trend observed for the Firmicutes phylum ([Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). Proteobacteria and Actinobacteria seem instead generally not influenced by the presence of *Blastocystis* with only one and two data sets, respectively, in which they appear significant. Specific species in these phyla can however still be strongly associated with *Blastocystis* presence (e.g., the proteobacterium *Oxalobacter formigenes* significant in 5 data sets, [Supplementary Figure **7**](#sup1){ref-type="supplementary-material"}) or absence (for example, the actinobacterium *Eggerthella* significant in 5 data sets, [Supplementary Figure 7](#sup1){ref-type="supplementary-material"}), suggesting that species-specific functional specialization has a higher ecological connection with *Blastocystis* than more general phylum-level characteristics.

We expanded the analysis on the association between *Blastocystis* and specific intestinal organisms by searching overall microbiome signatures predictive for the presence of the microorganism. Our previous work on such machine learning signatures ([@bib49]) showed that all the diseases considered here can be associated, with a variable degree of accuracy, with their microbiome structures. In the case of *Blastocystis*, we found that microbiome signatures ([Figure 6f](#fig6){ref-type="fig"}) are always statistically significant and are even stronger than for the disease. Importantly, this is true not only when considering specific data sets with an unbiased cross-validation procedure ([@bib49]), but also when predicting the presence of *Blastocystis* in a given data set considering only the samples from the other independent studies. This confirms that *Blastocystis*-positive microbiomes have distinguishing features that are consistent across populations, geography, and batch effects.

Overall, our analysis suggests that a consistent set of bacterial and archaeal organisms, and the overall composition of the microbiome, are associated with the presence (or absence) of *Blastocystis*. Interestingly, despite the many ecological associations found, microbiome diversity is instead not associated with the presence of *Blastocystis* ([Supplementary Figure 8](#sup1){ref-type="supplementary-material"}). Recent studies addressed the possible correlation between the presence of *Blastocystis* and other microbiome members that can of course also be influenced by other factors such as intestinal transit time. 16 S rRNA amplicon sequencing revealed a higher abundance of Clostridia, Ruminococcaceae and Prevotellaceae, among *Blastocystis*-colonized individuals, while Enterobacteriaceae were enriched in *Blastocystis*-free patients ([@bib8]). Two other studies found that individuals with an intestinal microbiome dominated by *Bacteroides* had less *Blastocystis* than those with *Ruminococcus* and *Prevotella*-driven enterotypes ([@bib4]; [@bib44]); this was interpreted in terms of a correlation between *Blastocystis* and species richness, since the *Bacteriodes*-driven enterotype has a lower species richness compared with the other enterotypes. The same authors, however, pointed out that species richness alone could not explain other observed trends, such as the correlation between *Blastocystis* carriage and BMI in Danish individuals. They thus argued that the presence of specific microbial species could influence the ability of the microorganism to thrive in the gut, but were unable to identify those species. Here we expand this concept on a much larger cohort size and higher taxonomic resolution, and provide a list of bacterial and archaeal organisms that should be prioritized in future experimental investigations (for example, *in vitro*) aimed at understanding the ecology of *Blastocystis* in the human gut and its potential direct interaction with bacterial members of the microbiome.

Discussion
==========

We have developed a computational pipeline to detect *Blastocystis* in human gut metagenomic samples and applied it to a collection of \>2000 metagenomes from subjects representing all continents except Australia and Antarctica. This is the largest investigation on the prevalence of *Blastocystis* and its subtypes in humans, overcoming in size and geographic diversity the single metagenomic study of an European cohort ([@bib4]) and the other more traditional investigations ([@bib10]; [@bib55]; [@bib60]; [@bib76]). Importantly, we also assessed the association between the presence of *Blastocystis* STs and a number of disease conditions, studied the co-occurrence (or co-exclusion) with other members of the gut microbiome, and reconstructed the genomes of strains belonging to different STs and used them for phylogenetic and functional potential analyses.

We detected *Blastocystis* in subjects from 11 of the 12 data sets, confirming its global distribution. In agreement with current literature, the geographic distribution of subtypes was not random: ST3 was widely distributed, ST4 was strongly underrepresented outside Europe and USA, and ST2 predominated in the non-industrialized cohorts. These findings illustrate how important epidemiologic aspects can be studied by mining appropriate metagenomics data sets.

We confirmed that the microorganism is able to persist for months ([@bib60]), and that all the *Blastocystis* STs commonly associated with humans are able to stably colonize the gut. The presence of *Blastocystis* was strongly negatively correlated with BMI, but microbiome diversity was not statistically associated with its presence, suggesting that the low microorganism prevalence in obese subjects is independent from the documented decrease in overall diversity ([@bib47]). Importantly, Blastocystis was significantly more prevalent in the control groups for the investigations on colorectal cancer and ulcerative colitis, and was absent in individuals with STEC infection (although no controls are available for this study). While these associations require additional follow-up studies, they are consistent with the general trend we observed of higher Blastocystis prevalence in healthy individuals. If we also consider the increased detection rate of the microorganism in non-westernized populations, its stable colonization in healthy subjects, and the high global prevalence, our work provides multiple and robust evidence to consider *Blastocystis* as a common member of the healthy human gut microbiome and further expands the findings of clinical studies of chronic colonization ([@bib57]) and carriage among healthy individuals ([@bib59]).

We completed the analysis by showing how the presence and abundance of *Blastocystis* were strongly correlated with those of Archaea; other bacterial species and phyla were similarly correlated (or anti-correlated) with *Blastocystis.* These analyses, which raise new hypotheses about potential ecological or direct interactions of *Blastocystis* with specific bacterial members of the gut microbiome, would have not been possible with purely cultivation-based approaches. Phylogenomic analyses are another essential tool for microbial population genomics, but are almost exclusively performed on genomes obtained by sequencing isolates ([@bib12]; [@bib29]). *Blastocystis* can be cultivated *in vitro* ([@bib70]), but establishing a collection of microorganism cultures from individuals of diverse geographic origin is very laborious and time-consuming. Here we show that full *Blastocystis* genomes can be reconstructed from metagenomes, and provide novel information on the diversity in the genus, the phylogenetic relation within subtypes and functional traits.

With the collections of publicly available metagenomes quickly growing in number and size, there is an unprecedented opportunity to unravel the population genomics of *Blastocystis* at multiple levels of resolution without the need of targeted isolation work. Importantly, the computational pipeline we developed here is applicable to other parasites and fungi, if genome information is available and the target organism is present at a sufficient abundance. We thus anticipate that metagenomic analysis coupled with the opportunity of mining the vast collections of gut metagenomes will soon become an indispensable tool to explore the epidemiology, genetics and diversity of Eukaryotic microorganisms in the human host.
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![Prevalence of *Blastocystis* and *Blastocystis* subtypes in the different data sets, different continents, different European states, and between westernized and non-westernized subjects (see [Supplementary Table 2](#sup1){ref-type="supplementary-material"} for more details). Stacked barplots show the prevalence in each category; numbers below the bars refer to the number of samples in the corresponding category, where duplicates from the same subject are eventually discarded. Statistical significance was assessed by Fisher\'s exact test.](ismej2017139f1){#fig1}

![*Blastocystis* prevalence in BMI classes (**a**) and different health conditions (**b**) for the considered data sets. Barplots show the prevalence of *Blastocystis* in different health conditions reported in the analyzed data sets. BMI classes considered were underweight (Un), normal (No), overweight (Ov) and obese (Ob). The total number of samples in each class and data set is reported below the bars. Bars associated with a total number of samples less than four are not shown. Note that scales in panels A and B are different. Abbreviations: CD, Crohn's disease; IGT, impaired glucose tolerance; T2D, type 2 diabetes; UC, ulcerative colitis. Fisher\'s exact test was used as statistical significance test.](ismej2017139f2){#fig2}

![Breadth of coverage (**a**) and relative abundance (**b**) of *Blastocystis* in subjects colonized over two timepoints (see [Supplementary Table 3](#sup1){ref-type="supplementary-material"} for more details). In the breadth of coverage plots, samples below the threshold of detection are also indicated. The breadth of coverage represents the fraction of the reference genome covered by at least one metagenomic read. The relative abundance is estimated by dividing the number of reads mapped to the *Blastocystis* reference genome with the total number of reads in the sample.](ismej2017139f3){#fig3}

![Phylogenetic relation between the 9 available *Blastocystis* reference genomes and 43 newly reconstructed genome assemblies from metagenomes. From the overall phylogenetic tree (**a**) we also report the subtrees of the four subtypes with more than 3 genomes (**b**--**e**) and compare the sequence diversity they span (**f**). Maximum likelihood phylogenetic trees were inferred using concatenated aligned shared genomic regions identified in reference genomes and assemblies (see Materials and methods). The asterisk highlights samples acquired from the same subject at two different timepoints. Black filled circles denote bootstrap support greater than 80%. The scale bar represents the average SNV rate calculated on the pairwise alignment.](ismej2017139f4){#fig4}

![Functional annotation analysis of the 19 reconstructed genomes spanning four *Blastocystis* STs. Less than half of the genes predicted by MAKER ([@bib13]) were assigned to known COG functional categories using the eggNOG ([@bib25]) database (**a**, see Materials and methods). These annotated genes can be grouped into 23 broad COG categories (**b**) that are a variable fraction of the total annotated genes. The asterisks denote categories for which one-way ANOVA statistical test gave *P*\<1E−04. Hierarchical clustering performed on the more specific KOG functions show that samples associated with the same ST cluster together (**c**).](ismej2017139f5){#fig5}

![The presence (or absence) of *Blastocystis* is associated with major differences in the intestinal microbiome. Some species are strongly associated with the presence (**a**--**c**) or absence (**d**) of *Blastocystis* (plots for additional microbes are reported in [Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). Boxplots report the distribution of abundances in samples with and without *Blastocystis*. Blue asterisks denote data sets where significant differences exist between the absence and presence of *Blastocystis*. LEfSe analysis (**e**) showed several other microorganisms statistically associated (α=0.05) with *Blastocystis* presence at high effect size (threshold at 3.3). Machine learning-based approach reveals that the microbiome signature is predictive for the presence of *Blastocystis* (**f**). This is valid not only when considering specific data sets with an unbiased cross-validation procedure, but also when predicting the presence of the parasite in a given data set considering only the samples from other independent studies (leave-one-data set-out approach).](ismej2017139f6){#fig6}

###### List and characteristics of the metagenomic data sets used in this study

  *Data set name*   *Condition*         *Country*                  *\# Subjects*   *\# Total samples*   *\# Samples with condition*[a](#t1-fn2){ref-type="fn"}   *\# Total reads (10*^*9*^)   *\# Reads per sample (10*^*6*^*) mean±std*   *Age (yrs) median (interquartile range)*   *Reference*
  ----------------- ------------------- -------------------------- --------------- -------------------- -------------------------------------------------------- ---------------------------- -------------------------------------------- ------------------------------------------ -------------
  Candela           Healthy             Italy, Tanzania            38              38                   ---                                                      0.85                         22.3±19.3                                    30 (23--38)                                [@bib56]
  HMP               Healthy             USA                        111             191                  ---                                                      20.50                        108.5±31.7                                   26 (23--28)                                [@bib26]
  Karlsson          T2D                 Denmark, 10 EU countries   145             145                  53                                                       4.49                         31.0±17.6                                    70 (69--71)                                [@bib27]
  Le Chatelier      Obesity             Denmark                    292             292                  169                                                      20.14                        69.0±23.2                                    56 (50--61)                                [@bib34]
  Liu               Healthy             China, Mongolia            110             110                  ---                                                      6.41                         58.2±26.8                                    ---                                        [@bib37]
  Loman             STEC infection      Germany                    37              44                   44                                                       0.39                         9.0±12.0                                     ---                                        [@bib38]
  MetaHIT           CD, UC              Denmark, Spain             124             124                  25                                                       5.60                         45.1±18.4                                    54 (49--60)                                [@bib51]
  Nielsen           CD, UC              Denmark, Spain             318             396                  148                                                      21.40                        53.9±20.2                                    49 (40--59)                                [@bib43]
  Obregon-Tito      Healthy             Peru, USA                  58              58                   ---                                                      2.73                         47.1±20.8                                    26 (17--35)                                [@bib45]
  Qin               Liver cirrhosis     China                      237             237                  123                                                      12.24                        51.6±30.9                                    45 (38--54)                                [@bib53]
  T2D               T2D                 China                      363             363                  170                                                      14.60                        40.2±11.8                                    48 (38--57)                                [@bib52]
  Zeller            Colorectal cancer   France                     156             156                  53                                                       9.37                         60.0±25.4                                    63 (58--70)                                [@bib81]
  Total                                                            1689            2154                 785                                                      118.72                       55.12±29.0                                   49 (36--62)                                 

Abbreviations: CD, Crohn's disease; STEC, Shiga-toxigenic *Escherichia coli*; T2D, type 2 diabetes; UC, ulcerative colitis.

Except for condition 'healthy'.
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